Mammotome Launches AutoCore™ Biopsy System for Single Insertion Core Needle Technology
Slice of Healthcare Team
Nov 08, 2024
Key Highlights
- Tiffany Salas-Morris appointed as Chief Commercial Officer (CCO)
- Over two decades of expertise in life sciences and biotech
- Will drive commercial strategy to expand market presence and customer engagement
- Focus on scaling cell mimic technology to support advanced therapies
Source: Business Wire
Notable Quote
“ Mammotome is dedicated to providing innovative solutions that improve the biopsy experience for both patients and physicians. The Mammotome AutoCore™ system is the first core needle device of its kind, bringing in a new era of efficiency for ultrasound core needle breast biopsies. The launch of this device is a testament to our ongoing dedication to innovation and excellence in breast care. ”
Karen Isaacs, Vice President of Engineering and R&D at Mammotome
